Eli Lilly & Co. (LLY): If You’re Going to Fail, Fail Quickly

Lilly calls active as shares soar; Put spreads constructed on Verizon, AT&TIn goes another drug into the Eli Lilly & Co. (NYSE:LLY) trash can. The pharma is dropping development of tabalumab for rheumatoid arthritis.

It’s not particularly surprising given that the drug failed a phase 3 trial in December, but it’s still disappointing for a company that could really use a positive result. Tabalumab joins in the trash can Alimta for lung cancer, pomaglumetad methionil for schizophrenia, and Forteo for back pain, which all recently failed clinical trials.

The trial results released in December showed that tabalumab failed to help patients who didn’t respond to methotrexate, a drug typically used early in disease progression. Based on that result, Eli Lilly decided to take an early look at its other study in patients who failed to respond to one or more tumor necrosis factor inhibitors — AbbVie Inc (NYSE:ABBV)‘s Humira, Johnson & Johnson (NYSE:JNJ) and Merck & Co., Inc. (NYSE:MRK)‘s Remicade, or Pfizer Inc. (NYSE:PFE) and Amgen, Inc. (NASDAQ:AMGN)‘s Enbrel — that are typically used later in the progression of rheumatoid arthritis. The interim peek at the data showed that it was futile to continue, so Lilly has decided to drop development of tabalumab in rheumatoid arthritis.

While Humira, Remicade, and Enbrel are safe from future competition from tabalumab, GlaxoSmithKline plc (ADR) (NYSE:GSK) still needs to watch its back. Eli Lilly is continuing development of tabalumab as a treatment for lupus. The drug attacks the same target — B cell activating factor, or BAFF — as Glaxo’s Benlysta, so the chance of success is higher for lupus.

Glaxo and its acquired partner Human Genome Sciences tested Benlysta on rheumatoid arthritis where it was shown to be ineffective, so it shouldn’t come as much of a surprise that tabalumab was ineffective as well.

I’m not sure exactly what led Lilly to believe it could succeed where Benlysta had failed, perhaps it felt tabalumab was a better inhibitor and could therefore succeed. Hindsight is 20/20, but it seems likely that BAFF isn’t a good target for rheumatoid arthritis. The only good decision we can say Lilly made in the development of tabalumab for rheumatoid arthritis is that it ended development early, saving money by not letting the trials go to completion before realizing that it was a dead end.

The article If You’re Going to Fail, Fail Quickly originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!